Wang, Xiuyan

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 2,688

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 2,063

Clinical manufacturing of CAR T cells: foundation of a promising therapy

Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 637

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., et al. (2021) · Cancer Discovery

CAR-T cell therapy researchCancer Immunotherapy and Biomarkers

Cited by 605

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., et al. (2019) · Science Translational Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 391

Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL).

Sauter, C. S., Riviere, I., Bernal, Y., Wang, X., Purdon, T., Yoo, S., Moskowitz, C. H., Giralt, S., Matasar, M. J., Curran, K. J., et al. (2015) · Journal of Clinical Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 36

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Mailankody, S., Diamonte, C., Fitzgerald, L., Kane, P., Wang, X., Sikder, D. S., Senechal, B., Bermudez, V. P., Frias, D., Morgan, J., et al. (2021) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 30